Cost-effectiveness of Stroke Prophylaxis for Nonvalvular Atrial Fibrillation

JAMA: The Journal of the American Medical Association

Volumn 275, Issue 12, 1996, Pages 909-

  Kan, Brian D ^a   Katz, David A ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

AGE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SURVIVAL;

EID: 85047691622     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.275.12.909     Document Type: Letter

References (3)

1. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
2. Kassirer JP, Pauker SG. The toss-up. N Engl J Med. 1981;305:1467-1469.
3. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.